Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06644625 · ClinicalTrials.gov registry record
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
A clinical trial of Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance (MGUS), sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- 1,665
- Enrollment target
- 1
- Study location
NCT06644625 is a study of Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance (MGUS) that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 1,665 participants, above the 543-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (207% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06644625, a study of Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance (MGUS), is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- 1,665 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.
Conditions Studied
Interventions
- OTHER Blood draw for the laboratory assessment
Study Locations (1)
North Carolina
- Atrium Health Levine Cancer - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,665 participants |
| Start Date | 2025-03-01 |
| Est. Completion | 2035-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06644625
The ClinicalTrials.gov registry entry for NCT06644625 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,665 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 543-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (207% higher). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Blood draw for the laboratory assessment is the first listed.
NCT06644625 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06644625 about?
NCT06644625 is a clinical study titled "CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study". The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.
What is the current status of trial NCT06644625?
This trial is currently recruiting. The enrollment target is 1,665 participants. The study started on 2025-03-01. Estimated completion is 2035-01.
What conditions does trial NCT06644625 study?
This clinical trial studies the following conditions: Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), Plasma Cell Disorders, Multiple Myeloma Progression.
What interventions are being tested in trial NCT06644625?
The interventions under investigation include: Blood draw for the laboratory assessment (OTHER).
Who is sponsoring clinical trial NCT06644625?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06644625 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Explore more on PlainTrial
Multiple Myeloma
All registered trials for this condition
Monoclonal Gammopathy of Undetermined Significance (MGUS)
All registered trials for this condition
North Carolina
All trials with a study site in North Carolina
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.